MYCN and neuroblastoma: Although NB is characterized by clinical and biological heterogeneity, on the base of age, tumor stage and genomic rearrangements (MYCN amplification and aneuploidy), the International Neuroblastoma Risk Group Staging System (INRGSS) classification divides patients in four groups, ranging from very low- to high-risk2.